专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018237010A2 VACCINE COMPOSITIONS AND METHODS OF USING THE SAME 审中-公开
公开(公告)号：WO2018237010A2
公开(公告)日：2018-12-27
申请号：PCT/US2018/038512
申请日：2018-06-20
申请人： THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
发明人： XIN, Hong
IPC分类号： A61K48/00
CPC分类号： C07K16/20 , A61K39/0002 , A61K2039/505 , A61K2039/5154 , A61K2039/58 , A61K2039/6081 , A61K2039/70 , C07K7/06 , C07K7/08 , C07K14/40 , C07K16/14 , C07K2317/34 , C12N9/0008 , C12N9/1007 , C12N9/1217 , C12N9/88
摘要： This invention is directed to vaccine compositions and methods of using the same to prevent infection.

2. 发明申请

WO2017156058A1 GITR ANTIBODIES, METHODS, AND USES 审中-公开
标题翻译： GITR抗体，方法和用途
公开(公告)号：WO2017156058A1
公开(公告)日：2017-09-14
申请号：PCT/US2017/021258
申请日：2017-03-08
申请人： JANSSEN BIOTECH, INC.
发明人： HOLLAND, Cam , KEHOE, John , SNYDER, Linda , SEPULVEDA, Alejandro , VILLAREAL, Daniel
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2878 , A61K39/0011 , A61K39/08 , A61K39/12 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/58 , A61K2039/585 , A61P31/04 , A61P31/20 , C07K16/2818 , C07K16/2827 , C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/567 , C07K2317/732 , C07K2317/75 , C07K2317/92 , C12N2710/16134 , A61K2300/00
摘要： Provided herein are antibodies that specifically bind to GITR. Also described are related polynucleotides capable of encoding the provided GITR-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to enhance an immune response in a subject against cancer.
摘要翻译：本文提供了特异性结合GITR的抗体。还描述了能够编码提供的GITR特异性抗体或抗原结合片段的相关多核苷酸，表达所提供的抗体或抗原结合片段的细胞，以及相关载体和可检测标记的抗体或抗原结合片段。另外，描述了使用提供的抗体的方法。例如，所提供的抗体可用于增强受试者对抗癌症的免疫应答。

3. 发明申请

WO2017143024A2 PATHOGEN VACCINES AND METHODS OF PRODUCING AND USING THE SAME 审中-公开
标题翻译：病原体疫苗及其制备和使用方法
公开(公告)号：WO2017143024A2
公开(公告)日：2017-08-24
申请号：PCT/US2017/018114
申请日：2017-02-16
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： ALI, Omar, Abdel-rahman , CARTWRIGHT, Mark, Joseph , DOHERTY, Edward , GRAVELINE, Amanda , INGBER, Donald, E. , MOONEY, David, J. , SEILER, Benjamin , STAFFORD, Alexander , SUPER, Michael , WHITE, Des
IPC分类号： A61K39/108
CPC分类号： A61K39/0258 , A61K39/025 , A61K2039/55522 , A61K2039/55561 , A61K2039/58 , A61K2039/6031 , A61K2039/6093 , Y02A50/474
摘要： The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein.
摘要翻译：本发明提供了疫苗组合物和生产这种组合物的方法。本发明的其它实施方案包括治疗病原体感染的方法，针对病原体感染接种受试者的方法，以及在有需要的受试者中治疗抗生素抗性细菌感染的方法。在进一步的实施方案中，本发明包括降低具有病原体感染的受试者中的病原体水平的方法，增加具有病原体感染的受试者的存活率的方法，降低与病原体感染相关的疼痛水平的方法，以及降低有此需要的受试者中与病原体感染相关的痛苦程度的方法。本文还提供了新的支架组合物和调理素结合或凝集素结合的病原体组合物及其用途。

4. 发明申请

WO2017081703A1 IN-SILICO METHOD TO IDENTIFY COMBINATORIAL PROTEINS AS IMMUNE-STIMULATORS AGAINST LEISHMANIASIS 审中-公开
标题翻译：用于鉴定组合蛋白作为针对利什曼病的免疫刺激剂的IN-SILICO方法
公开(公告)号：WO2017081703A1
公开(公告)日：2017-05-18
申请号：PCT/IN2016/050390
申请日：2016-11-09
申请人： COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
发明人： SARKAR, Ram Rup , GANGULI, Piyali , CHOWDHURY, Saikat
IPC分类号： G06F19/12
CPC分类号： G06F19/12 , A61K2039/58
摘要： The present invention discloses a combination of proteins influencing the survival of the Leishmania species inside the human cell and a process for regulating the expression the combination of proteins. Further, the present invention relates to the regulation of the combination of proteins to serve as immuno-stimulators to treat leishmaniasis.
摘要翻译：本发明公开了影响人类细胞内利什曼原虫存活的蛋白质的组合和调节蛋白质组合表达的过程。此外，本发明涉及调节蛋白质组合作为免疫刺激剂来治疗利什曼病。

5. 发明申请

WO2017068112A1 IMMUNOGENIC FUSION PROTEIN 审中-公开
标题翻译：免疫原性融合蛋白
公开(公告)号：WO2017068112A1
公开(公告)日：2017-04-27
申请号：PCT/EP2016/075356
申请日：2016-10-21
申请人： MINERVAX APS
发明人： PEDERSEN, Per Bo
IPC分类号： A61K39/09 , C07K14/315
CPC分类号： A61K39/092 , A61K2039/55505 , A61K2039/58 , A61K2039/70 , C07K14/315 , C07K2319/00
摘要： The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B streptococcus surface protein Alp1, Alp2, Alp3 or Alp4. The invention further pertains to an isolated nucleotide sequence encoding the immunogenic fusion protein; a vector; a host cell; an immunogenic product, a vaccine; and a method for preventing or treating a group B Streptococcus infection.
摘要翻译：本发明涉及免疫原性融合蛋白，其包含与第一组B链球菌表面蛋白的N端区域的氨基酸序列具有至少80％序列同一性的第一氨基酸序列，其与第二组B链球菌表面蛋白的N端区域的氨基酸序列具有至少80％的序列同一性的第二氨基酸序列融合。第一和第二组B链球菌表面蛋白中的每一种选自Rib蛋白，Alp1蛋白，Alp2蛋白，Alp3蛋白，Alp4蛋白和AlpC蛋白。免疫原性融合蛋白进一步包含与B族链球菌表面蛋白Alp1，Alp2，Alp3或Alp4的N端区域的氨基酸序列具有至少80％序列同一性的至少一个氨基酸序列。本发明还涉及编码免疫原性融合蛋白的分离的核苷酸序列; 一个向量; 宿主细胞; 免疫原性产品，疫苗; 以及预防或治疗B族链球菌感染的方法。

6. 发明申请

WO2017031404A1 LIVE-ATTENUATED VACCINE HAVING MUTATIONS IN VIRAL POLYMERASE FOR THE TREATMENT AND PREVENTION OF CANINE INFLUENZA VIRUS 审中-公开
标题翻译：具有病毒聚合酶突变的活体灭活疫苗用于治疗和预防犬流感病毒
公开(公告)号：WO2017031404A1
公开(公告)日：2017-02-23
申请号：PCT/US2016/047715
申请日：2016-08-19
申请人： UNIVERSITY OF ROCHESTER , CORNELL UNIVERSITY
发明人： MARTINEZ-SOBRIDO, Luis , NOGALES-GONZALEZ, Aitor , PARRISH, Colin
IPC分类号： A61K39/12 , A61K39/00
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/543 , A61K2039/552 , A61K2039/58 , C12N2760/16134
摘要： The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.
摘要翻译：本发明涉及治疗和预防犬流感病毒（CIV）和CIV相关病理学的组合物和方法。本发明部分地基于以下发现：CIV基因组的片段1和片段2中的各种突变，从而编码突变体PB2和PB1蛋白，使病毒变得温度敏感。

7. 发明申请

WO2017009873A1 VACCINE COMPOSITIONS 审中-公开
标题翻译：疫苗组合物
公开(公告)号：WO2017009873A1
公开(公告)日：2017-01-19
申请号：PCT/IN2016/050241
申请日：2016-07-15
申请人： BHARAT BIOTECH INTERNATIONAL LIMITED
发明人： SUMATHY, Kandaswamy , ELLA, Krishna Murthy
IPC分类号： A61K39/12 , C12N7/06
CPC分类号： A61K39/12 , A61K9/0019 , A61K47/02 , A61K47/183 , A61K47/26 , A61K47/42 , A61K2039/5252 , A61K2039/55505 , A61K2039/55511 , A61K2039/5555 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/55583 , A61K2039/58 , A61K2039/70 , C07K16/1081 , C12N2710/14143 , C12N2770/24134 , C12N2770/24151 , C12N2770/36134 , Y02A50/383 , Y02A50/39 , Y02A50/392
摘要： The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.
摘要翻译：本公开提供用于预防和治疗Zika病毒感染的疫苗组合物，其包含免疫原性组合物中的Zika病毒抗原，以及Zika抗原与一种或多种伞状病毒抗原如基孔肯雅病毒和日本脑炎病毒抗原的组合，制备和生产方法这种用于疫苗的组合物用于在哺乳动物中引发针对上述病原体的免疫应答。

8. 发明申请

WO2016162845A1 RECOMBINANT LUMPY SKIN DISEASE VIRUS KNOCK-OUT MUTANT AND USES THEREOF 审中-公开
标题翻译：重组皮肤病皮疹病毒突变体及其用途
公开(公告)号：WO2016162845A1
公开(公告)日：2016-10-13
申请号：PCT/IB2016/052008
申请日：2016-04-08
申请人： AGRICULTURAL RESEARCH COUNCIL
发明人： WALLACE, David Brian , MATHER, Arshad Saleh , KARA, Pravesh Deepak
IPC分类号： A61K39/12
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2710/24021 , C12N2710/24034 , C12N2710/24062
摘要： This invention relates to a live-attenuated recombinant lumpy skin disease virus knock-out mutant, wherein the interieukin-10-like gene or a functional part of the gene has been inactivated in the viral genome. The invention specifically relates to the recombinant lumpy skin disease virus knock-out mutant, pharmaceutical compositions comprising the knock-out mutant, methods of producing the knock out mutant and uses of the knock-out mutant.
摘要翻译：本发明涉及活的减毒重组块状皮肤病病毒敲除突变体，其中白介素-10样基因或该基因的功能部分已经在病毒基因组中失活。本发明具体涉及重组块状皮肤疾病病毒敲除突变体，包含敲除突变体的药物组合物，产生敲除突变体的方法和敲除突变体的用途。

9. 发明申请

WO2016161018A1 MECHANICALLY INTERLOCKING COMPLEXES 审中-公开
标题翻译：机械互锁复合
公开(公告)号：WO2016161018A1
公开(公告)日：2016-10-06
申请号：PCT/US2016/025066
申请日：2016-03-30
申请人： CITY OF HOPE
发明人： WILLIAMS, John , BZYMEK, Krzysztof, P. , HORNE, David , XIE, Jun
IPC分类号： C07K16/00 , C07K7/06 , C07K7/08 , A61K39/395
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/58 , A61K2039/64 , C07K7/06 , C07K7/08 , C07K14/7051 , C07K16/2869 , C07K2317/55 , C07K2317/60 , C07K2317/92 , C07K2319/00 , C07K2319/01
摘要： Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments, including those where a Fab-binding molecule (Fab binding moiety) linked to a steric hindering molecule (steric hindering chemical moiety) is mechanically interlocked (e.g., through noncovalent conjugation) with the antibody or antibody fragment. Also provided are compositions that form highly stable and versatile drug delivery and diagnostic compositions.
摘要翻译：本文提供包括抗体片段的官能化单克隆抗体（mAb），包括抗体片段，包括与空间阻碍分子（空间位阻化学部分）连接的Fab结合分子（Fab结合部分）通过非共价缀合（例如通过非共价共轭）与抗体或抗体片段。还提供了形成高度稳定和通用的药物递送和诊断组合物的组合物。

10. 发明申请

WO2016134288A1 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS 审中-公开
标题翻译：用于预防和治疗恶病毒感染的组合物和方法
公开(公告)号：WO2016134288A1
公开(公告)日：2016-08-25
申请号：PCT/US2016/018723
申请日：2016-02-19
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION
发明人： WOODFOLK, Judith Ann
IPC分类号： A61K39/00 , A61K39/125 , A61K39/145 , C07K14/005 , C07K16/10
CPC分类号： A61K39/12 , A61K2039/58 , C12N2770/32722 , C12N2770/32734 , C12Q1/70 , G01N33/56983
摘要： An analysis of human CD4 + T-cell epitopes of RV capsid proteins with cross- reactive potential was performed, peptide epitopes of RV-A16 capsid proteins VP1 and VP2 were identified, RV-specific CD4 + T cells were phenotyped for surface markers and cytokine profiles using flow cytometry, and it was found that, among non-infected subjects, circulating RV-A16- specific CD4 + T cells detected at the highest frequencies targeted 10 unique epitopes with diverse HLA-DR binding capacity. T-cell epitopes localized to conserved regions of significance to the virus and were enriched for HLA class I and II binding motifs and were activated in vivo after experimental infection with RV-A16. RV-A16 epitopes constituted species-specific and pan-species varieties, together providing ~90% coverage of the US population. Cross-reactivity was evidenced for RV-A16 and RV-A39. High-frequency circulating RV-specific memory Th1 cells in healthy individuals preferentially target a limited set of conserved epitopes and these epitopes, separately or combined, can serve as vaccines.
摘要翻译：进行了具有交叉反应电位的RV衣壳蛋白的人CD4 + T细胞表位的分析，鉴定了RV-A16衣壳蛋白VP1和VP2的肽表位，RV特异性CD4 + T细胞被表型用于表面标志物和细胞因子谱流式细胞术，发现在非感染受试者中，以最高频率检测到的循环RV-A16特异性CD4 + T细胞靶向具有不同HLA-DR结合能力的10个独特表位。 T细胞表位位于对病毒有重要意义的保守区域，并且被富集为HLA I类和II类结合基序，并且在用RV-A16实验感染后在体内被活化。 RV-A16表位构成物种特异性和泛物种，共提供了约90％的美国人口覆盖率。 RV-A16和RV-A39证实了交叉反应性。健康个体的高频循环RV特异性记忆Th1细胞优先靶向有限的一组保守表位，这些表位分开或组合可用作疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式